Actively Recruiting
Study of XTX501 Monotherapy in Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors Evaluating Safety and Antitumor Activity
Led by Xilio Development, Inc. · Updated on 2026-11-04
180
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an open-label, first-in-human Phase 12 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of XTX501 in participants with metastatic non-small cell lung cancer NSCLC and certain advanced solid tumors. This multicenter trial aims to determine maximum tolerated doses and recommended Phase 2 doses to further assess treatment effects. The study includes two parts in Phase 1 Part 1A uses a Bayesian Optimal Interval design to find the maximum tolerated dose of XTX501 monotherapy across up to 10 dosing regimens, enrolling up to 60 participants. Part 1B evaluates safety and antitumor activity at doses considered for Phase 2. Phase 2 then expands to study efficacy of the selected doses in up to 80 participants with metastatic NSCLC. Participants will undergo regular safety monitoring including assessment of dose limiting toxicities, treatment-emergent and serious adverse events, and laboratory value changes. The study also measures objective response rates and other tumor-related outcomes per RECIST v1.1 criteria, along with pharmacokinetic and immunogenicity markers. Safety follow-up continues for approximately 90 days after the last dose. Total participation duration varies based on dose escalation and treatment phases.
CONDITIONS
Brief Title
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
Research Team
X
Xilio Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here